Incorporating Molecular Data Into Treatment Decision Making in Gastroesophageal and Pancreaticobiliary Cancers:...

Area of Science:

• Oncology
• Molecular Biology
• Clinical Therapeutics

Background:

• Gastroesophageal (GE) and pancreatobiliary (PB) cancers pose significant clinical challenges.
• Understanding key molecular targets, their assays, and clinical actionability is critical for effective management.
• Integrating biomarkers into standard care is essential for refining treatment paradigms.

Purpose of the Study:

• To explore the complexities of molecular targets and biomarkers in GE and PB cancers.
• To provide insights into the optimal sequencing of chemotherapy and targeted therapies.
• To guide future clinical trial designs and advance patient care.

Main Methods:

• This review synthesizes current knowledge on molecular targets and biomarkers in GE and PB cancers.
• It analyzes the clinical utility and actionability of identified targets.
• The review examines evidence for sequencing chemotherapy and targeted agents.

Main Results:

• Key molecular targets and their corresponding assays in GE and PB cancers are identified.
• The clinical actionability and therapeutic potential of these targets are discussed.
• Optimal strategies for integrating chemotherapy and targeted therapies are outlined.

Conclusions:

• Integrating molecular insights and biomarkers is vital for advancing GE and PB cancer treatment.
• Refined sequencing of therapies holds promise for improved patient outcomes.
• This review offers guidance for navigating the evolving landscape of GE and PB cancer care.